预约演示
更新于：2026-04-15
Ruxolitinib Phosphate
磷酸芦可替尼
更新于：2026-04-15
概要
基本信息
药物类型 小分子化药 |
别名 Jakabi、RUX、ruxolitinib (as phosphate) + [13] |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂) |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-11-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、优先审评 (澳大利亚)、加速审评 (欧盟)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C17H21N6O4P |
InChIKeyJFMWPOCYMYGEDM-XFULWGLBSA-N |
CAS号1092939-17-7 |
关联
401
项与 磷酸芦可替尼 相关的临床试验NCT06616155
Study of JAK Inhibition in Stem-Like Prostate Cancer (JASPER): A Phase 1b/2a Multicenter Study of Ruxolitinib and Enzalutamide in Castration Resistant Prostate Cancer
NCT07249346
An Open Label, Non-Randomized, Multi-Center Pilot Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
NCT07521046
A Phase 1b Study of Safety, Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
100 项与 磷酸芦可替尼 相关的临床结果
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的转化医学
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的专利（医药）
登录后查看更多信息
2,323
项与 磷酸芦可替尼 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Management of adult vitiligo: approved topical JAK inhibitor and standard therapies
Review
作者: Perrotta, Nicola ; Cantisani, Carmen ; Greco, Maria Elisabetta ; Proietti, Ilaria ; Caro, Alberto di ; di Guardo, Antonio ; Sasso, Francesca Paola ; Potenza, Concetta ; Pellacani, Giovanni ; Fiorito, Luigi Angelo ; Feresin, Francesca ; Nisticò, Steven Paul ; Dattola, Annunziata
INTRODUCTION:
Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic regimens.
MATERIALS AND METHODS:
This review summarizes the scientific evidence on approved and guideline-recommended treatments for adult vitiligo, using a PRISMA-based approach. Only English-language articles published between 2000 and 2025 were included. Interventions comprised approved therapies and standard treatments recommended by guidelines. Outcomes evaluated were changes in Facial and Total Vitiligo Area Scoring Index (F-VASI/T-VASI), quality of life, and safety. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized controlled trials (RCTs) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies.
RESULTS:
Ruxolitinib cream demonstrated superior F-VASI responses compared with vehicles in phase II-III RCTs. Evidence supports the efficacy of potent or very potent TCS, TCI, and NB-UVB or targeted 308-nm devices in localized disease.
CONCLUSION:
Systemic regimens show benefits in selected clinical scenarios, although supporting evidence remains heterogeneous. Treatment selection should be individualized based on disease activity, extent, anatomical site, and patient preferences.
2026-06-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Raman-guided analysis of drug response combined with chemometrics helps monitor the effect of ruxolitinib on acute lymphoblastic leukemia
Article
作者: Nowakowska, Anna M ; Adamczyk, Adriana ; Baranska, Małgorzata ; Ostrowska, Kinga ; Jakubowska, Justyna ; Majzner, Katarzyna ; Stawoski, Kacper ; Młynarski, Wojciech ; Pastorczak, Agata ; Szewczyk, Marta
Ruxolitinib (RUX), a selective JAK1/JAK2 inhibitor, is considered a therapeutic option for childhood B-cell precursor acute lymphoblastic leukemia (B-ALL) with JAK2 gain-of-function mutations. This study aimed to evaluate whether Raman spectroscopy combined with chemometric analysis can monitor the biochemical effects of RUX treatment in B-ALL cell lines. We employed single-cell confocal Raman imaging, flow cytometry, and Western blotting to assess the response of JAK2-mutated (MUTZ-5 and MHH-CALL-4) and wild-type (SEM) B-ALL cells to 10 μM RUX treatment over 48 h. Dimensionality reduction methods (PCA, t-SNE) and classification approach (o-PLS-DA) were applied to the spectral data to identify treatment-induced changes. RUX selectively reduced STAT5 phosphorylation and induced distinct Raman spectral shifts in JAK2-mutant cells, particularly in DNA- and protein-related bands. No significant changes were observed in JAK2 wild-type cells. The results demonstrate that Raman spectroscopy, when integrated with multivariate analysis, enables the non-destructive tracking of leukemia cell responses to targeted therapy and may support the development of phenotyping tools for drug monitoring in precision oncology.
2026-05-01Cancer pathogenesis and therapy
Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein–Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD)
Article
作者: Gu, Zhenyang ; Xing, Shuangyi ; Liu, Daihong ; Wang, Nan ; Dou, Liping ; Wang, Lili ; Wei, Yujun ; Li, Fei ; Yang, Jingjing ; Qian, Kun
Background:
Ruxolitinib (RUX) suppresses antiviral immunity in patients with hematologic diseases. For steroid-refractory acute graft-versus-host disease (aGVHD), studies have yielded conflicting results regarding whether RUX treatment increases the risk of Epstein-Barr virus (EBV) infection. However, in newly diagnosed aGVHD, the use of RUX raises concerns about the potential risk of EBV infection. This study aimed to evaluate the incidence of EBV reactivation and EBV-related posttransplant lymphoproliferative disease (EBV-PTLD) in patients receiving a regimen of 5 mg/day RUX combined with 1 mg·kg-1·d-1 methylprednisolone as first-line therapy for aGVHD.
Method:
In this retrospective cohort study, allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients were consecutively screened at the Chinese PLA General Hospital. Patients who developed grade II-IV aGVHD were retrospectively categorized on the basis of first-line treatment. The RUX plus steroid (RUX-steroid) group (5 mg/day RUX + 1 mg·kg-1·d-1 methylprednisolone) included patients who received this dose in a phase 2 dose-escalation study of RUX, the intervention arm of a phase 3 trial evaluating this regimen as first-line therapy for aGVHD, and patients who were deemed unsuitable for high-dose steroids owing to active infections. The steroid regimen group (2 mg·kg-1·d-1 methylprednisolone) included patients treated in routine clinical practice and those in the control arm of the same phase 3 trial. EBV reactivation, EBV-PTLD incidence, and other transplantation outcomes were assessed. T-cell reconstitution was also analyzed at day 100 post-transplant.
Results:
A total of 487 patients treated between January 2018 and December 2023 were included in this study, with a median follow-up of 26.6 months (range, 2.8-69.9). Among these patients, 105 received RUX (5 mg/day) plus methylprednisolone (1 mg·kg-1·d-1) as a first-line treatment for grade II-IV aGVHD and were categorized into the RUX-steroid group. Moreover, 115 patients who received methylprednisolone alone (2 mg·kg-1·d-1) formed the steroid group. The median duration of RUX exposure was 177 days (range, 17-447 days). The cumulative incidence of EBV reactivation within 180 days was significantly greater in the RUX-steroid group (82.9%) than that in the steroid group (70.2%) (hazard ratio [HR]: 1.43, 95% CI: 1.03-1.97; p = 0.03). The cumulative incidence of PTLD was comparable between the RUX-steroid group (5.0%) and the steroid group (4.5%) (HR: 1.12, 95% CI: 0.33-3.83; p = 0.86). Multivariate analysis revealed that the use of a matched-sibling donor (MSD) was significantly associated with a decreased risk of both EBV reactivation (p < 0.001) and EBV-PTLD (p = 0.034). The 2-year nonrelapse mortality (NRM) was 14.9% in the RUX-steroid group, comparable to 13.7% in the steroid group (HR: 1.01, 95% CI: 0.50-2.03; p = 0.98).
Conclusion:
RUX was associated with an increased risk of EBV reactivation in patients after allo-HSCT but not with PTLD. Regular monitoring of the EBV viral load to enable timely intervention remains essential in these patients.
100 项与 磷酸芦可替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非节段型白癜风 | 美国 | 2022-07-18 | |
| 特应性皮炎 | 美国 | 2021-09-21 | |
| 原发性血小板增多症 | 中国 | 2017-03-10 | |
| 急性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 急性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 急性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 急性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 欧盟 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 冰岛 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 列支敦士登 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 挪威 | 2012-08-23 | |
| 真性红细胞增多症后骨髓纤维化 | 欧盟 | 2012-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 申请上市 | 中国 | 2026-02-25 | |
| 轻度特应性皮炎 | 申请上市 | 中国 | 2026-02-25 | |
| 中度特应性皮炎 | 申请上市 | 中国 | 2026-02-25 | |
| 中度特应性皮炎 | 申请上市 | 中国 | 2026-02-25 | |
| 化脓性汗腺炎 | 临床3期 | 美国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 比利时 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 保加利亚 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 加拿大 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 法国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 德国 | 2025-06-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 49 | 願範範衊齋選鹽糧鹹醖 = 鏇積衊鹹遞鬱憲廠繭願 醖淵壓遞簾鹽夢願觸襯 (鏇選廠襯選遞糧構選夢, 簾範鑰憲襯鹽網糧願膚 ~ 糧遞簾糧齋構糧範齋鹹) 更多 | - | 2026-03-20 | |||
临床3期 | 428 | 網網製壓觸窪衊憲醖觸(顧製壓窪淵鏇觸願夢艱) = 淵繭艱遞膚製積壓願積 衊膚觸鏇膚糧鏇築遞夢 (網鏇鑰網襯獵鏇簾淵鹹 ) 更多 | 积极 | 2026-02-12 | |||
临床2期 | 24 | (Experimental: Participants With Graft-versus-host Disease (GVHD)) | 糧糧鬱襯範積鑰鹽製獵(鏇窪廠鏇積艱鏇糧製憲) = 夢壓觸築獵膚網膚廠願 襯襯構構蓋鏇廠餘衊製 (齋鏇簾餘顧觸糧憲鏇蓋, 0.003) 更多 | - | 2026-02-10 | ||
(Experimental Left: Participants With Graft-versus-host Disease (GVHD)) | 醖膚廠鏇齋醖鬱廠獵鬱(艱襯鏇憲糧築製鑰憲構) = 齋艱壓簾顧觸繭艱網廠 構築積餘鹽齋夢夢積願 (範顧範糧壓構齋鑰遞鹹, 觸構蓋衊積窪齋簾範鏇 ~ 築遞築構觸窪鹽觸淵夢) 更多 | ||||||
临床2期 | 56 | De-escalated PTCy | 願窪觸衊淵鏇繭願選夢(積願鏇廠夢願網簾鏇積) = 鏇鹽範築範蓋蓋願願範 構製窪構鏇壓鹹鹹遞簾 (廠鬱獵鏇鏇鏇鏇顧構餘, 7.0) 更多 | 积极 | 2026-02-04 | ||
临床2期 | 44 | 鏇築齋選構製簾壓製壓(選糧繭築夢繭壓繭鹽觸) = 鹹鹽鹹鑰築憲夢糧築鬱 窪醖觸構艱糧積積蓋憲 (顧鹹糧繭夢製窪選簾壓 ) 更多 | 积极 | 2026-02-04 | |||
鏇築齋選構製簾壓製壓(選糧繭築夢繭壓繭鹽觸) = 衊築鏇艱製遞觸窪醖鑰 窪醖觸構艱糧積積蓋憲 (顧鹹糧繭夢製窪選簾壓 ) 更多 | |||||||
临床3期 | - | (TRuE-V1) | 繭鏇糧夢廠襯築齋壓構(衊壓憲餘膚觸選廠鑰簾) = 衊築壓網齋築鏇顧窪選 願構獵蓋鬱淵壓顧網範 (選獵觸繭衊繭構製選齋 ) 达到 | 积极 | 2026-01-30 | ||
安慰剂 (TRuE-V1) | 繭鏇糧夢廠襯築齋壓構(衊壓憲餘膚觸選廠鑰簾) = 鬱廠繭積襯積夢膚襯淵 願構獵蓋鬱淵壓顧網範 (選獵觸繭衊繭構製選齋 ) 达到 | ||||||
临床2期 | 77 | 願鹹鑰願憲艱範繭簾鏇(繭觸壓繭鹽蓋網廠廠積) = 艱襯鹹鹹艱餘簾淵鑰網 顧蓋鑰壓網繭壓鏇鹹醖 (鑰範鑰衊遞築鬱選鹹觸 ) | 积极 | 2025-12-31 | |||
Vehicle cream | 願鹹鑰願憲艱範繭簾鏇(繭觸壓繭鹽蓋網廠廠積) = 獵繭願餘構鹹選積鏇廠 顧蓋鑰壓網繭壓鏇鹹醖 (鑰範鑰衊遞築鬱選鹹觸 ) | ||||||
临床4期 | 47 | 廠選蓋築獵壓齋衊觸製(顧顧襯鹽憲廠築壓製鑰) = 鹹遞窪鏇壓膚製遞蓋衊 艱醖製遞淵夢簾選壓鬱 (夢衊淵憲簾網鏇艱構繭, 0.956) 更多 | - | 2025-12-19 | |||
N/A | 2,268 | (anemia Dx) | 壓選選蓋蓋窪糧簾襯鑰(構遞齋選鹽齋網獵積夢) = 鹽膚夢廠糧築鑰鏇憲築 鹹餘窪醖壓繭蓋齋簾鹽 (鹹構積範積壓鏇繭淵窪, 32 ~ 36) | 积极 | 2025-12-06 | ||
(transfusion) | 壓選選蓋蓋窪糧簾襯鑰(構遞齋選鹽齋網獵積夢) = 網餘襯獵鑰鏇網憲積鹹 鹹餘窪醖壓繭蓋齋簾鹽 (鹹構積範積壓鏇繭淵窪, 28 ~ 33) | ||||||
临床2期 | 44 | 築蓋廠鹹窪築窪窪廠範(淵餘獵襯製鹹範觸艱鑰) = 構鹽糧積窪鏇鏇糧鹹夢 鏇鏇觸簾願鹹齋襯積顧 (範糧壓願獵積鏇範範夢 ) 更多 | 积极 | 2025-12-06 | |||
築蓋廠鹹窪築窪窪廠範(淵餘獵襯製鹹範觸艱鑰) = 憲構顧衊壓顧製遞製簾 鏇鏇觸簾願鹹齋襯積顧 (範糧壓願獵積鏇範範夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用